Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 30-38

  Stanczyk, Frank Z ^a   Bhavnani, Bhagu R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Androgen receptor; Breast cancer; Cardiovascular disease; Medroxyprogesterone acetate; Neuroprotection

Indexed keywords

ANDROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE;

BLOOD CLOTTING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; COGNITIVE DEFECT; DRUG METABOLISM; DRUG SAFETY; EPITHELIUM CELL; HEART FUNCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAMMOGRAPHY; NONHUMAN; OBSERVATIONAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EQUIDAE;

ANDROGEN RECEPTOR; BREAST CANCER; CARDIOVASCULAR DISEASE; MEDROXYPROGESTERONE ACETATE; NEUROPROTECTION;

ANIMALS; BLOOD COAGULATION; BRAIN; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COGNITION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; POSTMENOPAUSE;

EID: 84899940681     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.11.011     Document Type: Review

References (69)

1. L. Campio, G. Robustelli Della Cuna, and R.W. Taylor Role of Medroxyprogesterone in Endocrine-related Tumors Vol. 2 1983 Raven Press New York
2. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene, and Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
3. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, S. Wassertheil-Smoller, and Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
4. R. Sitruk-Ware New progestagens for contraceptive use Hum. Reprod. Update 12 2006 169 178
5. J.W. Zhang, Y. Liu, J.Y. Zhao, L.M. Wang, G.B. Ge, Y. Gao, W. Li, H.T. Liu, H.X. Liu, Y.Y. Zhang, J. Sun, and L. Yang Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate Drug Metab. Dispos. 36 2008 2292 2298
6. A.K. Ropponen, K. Aittomäki, V. Vihma, M.J. Tikkanen, and O. Ylikorkala Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy J. Clin. Endocrinol. Metab. 90 2005 3431 3434
7. M. Hiroi, F.Z. Stanczyk, U. Goebelsmann, P.F. Brenner, M.E. Lumkin, and D.R. Mishell Jr. Radioimmunoassay of serum progesterone acetate (Provera® in women following oral and intravaginal administration Contraception 26 1975 373 386
8. L.O. Svensson, S.H. Johnson, and S.E. Olsson Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera and Divina. A randomized, single-blind, triple cross-over bioavailability study in menopausal women Maturitas 18 1994 229 238
9. A. Victor, and E.D. Johansson Pharmacokinetic observations on medroxyprogesterone acetate administered orally and vaginally Contraception 14 1976 319 329
10. A. Järvinen, P. Kainulainen, M. Nissilä, H. Nikkanen, and M. Kela Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women Maturitas 47 2004 209 217
11. S.N. Birrell, L.M. Butler, J.M. Harris, G. Buchanan, and W.D. Tilley Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer FASEB J. 21 2007 2285 2293
12. C.L. Shufelt, and G.D. Braunstein Testosterone and the breast Menopause Int. 14 2008 117 122
13. J.T. Anim, B. John, S. Abdulsathar, S.S. Prasad, A. Saji, T. Akhtar, V. Ali, and M. Al-Saleh Relationship between the expression of various markers and prognostic factors in breast cancer Acta Histochem. 107 2005 87 93
14. S.N. Birrell, D.M. Roder, D.J. Horsfall, J.M. Bentel, and W.D. Tilley Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression J. Clin. Oncol. 13 1995 1572 1577
15. F.A. Teulings, H.A. van Gilse, M.S. Henkelman, H. Portengen, and J. Alexieva-Figusch Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer Cancer Res. 40 1980 2557 2561
16. G. Buchanan, S.N. Birrell, A.A. Peters, T. Bianco-Miotto, K. Ramsay, E.J. Cops, M. Yang, J.M. Harris, H.A. Simila, N.L. Moore, J.M. Bentel, C. Ricciardelli, D.J. Horsfall, L.M. Butler, and W.D. Tilley Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate Cancer Res. 65 2005 8487 8496
17. J.M. Bentel, S.N. Burrell, M.A. Pickering, D.J. Holds, D.J. Horsfall, and W.D. Tilley Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate in human breast cancer cells Mol. Cell. Endocrinol. 154 1999 11 20
18. J.A. Kemppainen, E. Langley, C.I. Wong, K. Bobseine, W.R. Kelce, and E.M. Wilson Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone Mol. Endocrinol. 13 1999 440 454
19. G. Söderqvist, E. Isaksson, B. von Schoultz, K. Carlström, E. Tani, and L. Skoog Proliferation of breast epithelial cells in healthy women during the menstrual cycle Am. J. Obstet. Gynecol. 176 1997 123 128
20. R.P. Ghatge, B.M. Jacobsen, S.A. Schittone, and K.B. Horwitz The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells Breast Cancer Res. 7 2005 R1036 R1050
21. C.E. Wood, T.C. Register, and J.M. Cline Transcriptional profiles of progestogen effects in the postmenopausal breast Breast Cancer Res. Treat. 114 2009 233 242
22. C.E. Wood, T.C. Register, C.J. Lees, H. Chen, S. Kimrey, and J.M. Cline Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys Breast Cancer Res. Treat. 101 2007 125 134
23. L.J. Hofseth, A.M. Raafat, J.R. Osuch, D.R. Pathak, C.A. Slomski, and S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J. Clin. Endocrinol. Metab. 84 1999 4559 4565
24. D. Murkes, P. Conner, K. Leifland, E. Tani, A. Beliard, E. Lundström, and G. Söderqvist Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women Fertil. Steril. 95 2011 1188 1191
25. F.Z. Stanczyk, and S.A. Winer Effect of hormone therapy on breast epithelial cell proliferation Menopause 20 2013 483 485
26. L. Speroff, and M.A. Fritz Clinical Gynecologic Endocrinology and Infertility 2005 Lippincott Williams & Wilkins Philadelphia 736
27. G.A. Greendale, B.A. Reboussin, A. Sie, H.R. Singh, L.K. Olson, O. Gatewood, L.W. Bassett, C. Wasilauskas, T. Bush, and E. Barrett-Connor Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators Ann. Intern. Med. 130 1999 262 269
28. J.A. Collins, J.M. Blake, and P.G. Crosignani Breast cancer risk with postmenopausal hormone treatment Hum. Reprod. Update 11 2005 545 560
29. V. Beral Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427 (Erratum in: Lancet. 362 (2003) 1160)
30. A. Fournier, F. Berrino, and F. Clavel-Chapelon Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study Breast Cancer Res. Treat. 107 2008 103 111
31. J.C. Dinger, L.A. Heinemann, S. Möhner, M. Thai do, and A. Assmann Breast cancer risk associated with different HRT formulations: a register-based case-control study BMC Womens Health 6 2006 13
32. R.T. Chlebowski, S.L. Hendrix, R.D. Langer, M.L. Stefanick, M. Gass, D. Lane, R.J. Rodabough, M.A. Gilligan, M.G. Cyr, C.A. Thomson, J. Khandekar, H. Petrovitch, A. McTiernan WHI Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 2003 3243 3253
33. D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlatky, J. Hsia, S. Hulley, A. Herd, S. Khan, L.K. Newby, D. Waters, E. Vittinghoff, N. Wenger, and HERS Research Group Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 288 2002 49 57 (Erratum in: JAMA. 288 (2002) 1064)
34. J.E. Rossouw, R.L. Prentice, J.E. Manson, L. Wu, D. Barad, V.M. Barnabei, M. Ko, A.Z. LaCroix, K.L. Margolis, and M.L. Stefanick Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477 (Erratum in: JAMA. 299 (2008) 1426)
35. S. Toh, S. Hernández-Díaz, R. Logan, J.E. Rossouw, and M.A. Hernán Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial Ann. Intern. Med. 152 2010 211 217
36. J.E. Rossouw, M. Cushman, P. Greenland, D.M. Lloyd-Jones, P. Bray, C. Kooperberg, M. Pettinger, J. Robinson, S. Hendrix, and J. Hsia Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy Arch. Intern. Med. 168 2008 2245 2253
37. R.A. Wild, C. Wu, J.D. Curb, L.W. Martin, L. Phillips, M. Stefanick, M. Trevisan,J.E. Manson
38. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199 208 (Erratum in: JAMA. 274 (1995) 1676)
39. I.F. Godsland Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000 Fertil. Steril. 75 2001 898 915
40. S. Kalyan, C.L. Hitchcock, S. Sirrs, M. Pudek, and J.C. Prior Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy Pharmacotherapy 30 2010 442 452
41. M.J. Luckas, T. Gleeve, M.M. Biljan, W.M. Buckett, I.A. Aird, A. Drakeley, and C.R. Kingsland The effect of progestagens on the carotid artery pulsatility index in postmenopausal women on oestrogen replacement therapy Eur. J. Obstet. Gynecol. Reprod. Biol. 76 1998 221 224
42. J.K. Williams, E.K. Honoré, S.A. Washburn, and T.B. Clarkson Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys J. Am. Coll. Cardiol. 24 1994 1757 1761
43. R.G. Mishra, R.K. Hermsmeyer, K. Miyagawa, P. Sarrel, B. Uchida, F.Z. Stanczyk, K.A. Burry, D.R. Illingworth, and F.J. Nordt Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys J. Clin. Endocrinol. Metab. 90 2005 3706 3714
44. K. Miyagawa, J. Vidgoff, and K. Hermsmeyer Ca2+ release mechanism of primate drug-induced coronary vasospasm Am. J. Physiol. 272 1997 H2645 H2654
45. R.D. Minshall, F.Z. Stanczyk, K. Miyagawa, B. Uchida, M. Axthelm, M. Novy, and K. Hermsmeyer Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys J. Clin. Endocrinol. Metab. 83 1998 649 659
46. T.B. Clarkson, and S.E. Appt MPA and postmenopausal coronary artery atherosclerosis revisited Steroids 68 2003 941 951
47. M.C. Wender, F. Vigo, P.P. Oliveira, F. Bittellbrun, A.P. Furtado, L. Schvartzman, E. Capp, and F.M. de Freitas Effect of conjugated estrogen versus conjugated estrogen associated with medroxyprogesterone acetate in postmenopausal women on internal carotid artery pulsatility index: a randomized pilot study J. Obstet. Gynaecol. Res. 37 2011 815 818
48. M.A. Duzenli, K. Ozdemir, A. Sokmen, K. Gezginc, A. Soylu, C. Celik, B.B. Altunkeser, and M. Tokac The effects of hormone replacement therapy on myocardial performance in early postmenopausal women Climacteric 13 2010 157 170
49. M. Canonico, G. Plu-Bureau, G.D. Lowe, P.Y. Scarabin
50. M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Lévesque, N. Trillot, M.T. Barrellier, D. Wahl, J. Emmerich, P.Y. Scarabin, and Estrogen and Thromboembolism Risk (ESTHER) Study Group Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study Circulation 115 2007 840 845
51. S. Sweetland, V. Beral, A. Balkwill, B. Liu, V.S. Benson, M. Canonico, J. Green, G.K. Reeves The Million Women Study Collaborators Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study J. Thromb. Haemost. 2012 (Sep) 10.1111/j. 1538-7836.2012.04919.x
52. M.R. Vickers, A.H. MacLennan, B. Lawton, D. Ford, J. Martin, S.K. Meredith, B.L. DeStavola, S. Rose, A. Dowell, H.C. Wilkes, J.H. Darbyshire, T.W.T.W. Meade WISDOM group Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women BMJ 335 2007 239
53. M. Canonico, G. Plu-Bureau, and P.Y. Scarabin Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Maturitas 70 2011 354 360
54. C. Westhoff Risk of pulmonary embolism/venous thrombosis R. Lobo, Treatment of the Postmenopausal Woman, Basic and Clinical Aspects 3rd edition 2007 Academic Press Burlington, Massachusetts 491 500
55. D.W. Wright, A.L. Kellermann, V.S. Hertzberg, P.L. Clark, M. Frankel, F.C. Goldstein, J.P. Salomone, L.L. Dent, O.A. Harris, D.S. Ander, D.W. Lowery, M.M. Patel, D.D. Denson, A.B. Gordon, M.M. Wald, S. Gupta, S.W. Hoffman, and D.G. Stein ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury Ann. Emerg. Med. 49 2007 391 402
56. G. Xiao, J. Wei, W. Yan, W. Wang, and Z. Lu Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial Crit. Care 12 2008 R61
57. D.W. Wright, S.W. Hoffman, S. Virmani, and D.G. Stein Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats Brain Inj. 22 2008 107 113
58. J. Nilsen, and R.D. Brinton Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate Endocrinology 143 2002 205 212
59. J. Nilsen, and R.D. Brinton Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling Proc. Natl. Acad. Sci. U. S. A. 100 2003 10506 10511
60. J. Nilsen, A. Morales, and R.D. Brinton Medroxyprogesterone acetate exacerbates glutamate excitotoxicity Gynecol. Endocrinol. 22 2006 355 361
61. I. Ciriza, P. Carrero, C.A. Frye, and L.M. Garcia-Segura Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective J. Neurobiol. 66 2006 916 928
62. F. Bernardi, N. Pluchino, M. Pieri, S. Begliuomini, E. Lenzi, S. Puccetti, E. Casarosa, M. Luisi, A.R. Genazzani, and Progesterone medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels Neuroendocrinology 83 2006 348 359
63. P.K. Jodhka, P. Kaur, W. Underwood, J.P. Lydon, and M. Singh The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression Endocrinology 150 2009 3162 3168
64. R.W. Irwin, J. Yao, S.S. Ahmed, R.T. Hamilton, E. Cadenas, and R.D. Brinton Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function Endocrinology 152 2011 556 567
65. R.W. Irwin, J. Yao, R.T. Hamilton, E. Cadenas, R.D. Brinton, and J. Nilsen Progesterone and estrogen regulate oxidative metabolism in brain mitochondria Endocrinology 149 2008 3167 3175
66. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, J.K. Ockene, S.L. Hendrix, B.N. Jones 3rd, A.R. Assaf, R.D. Jackson, J.M. Kotchen, S. Wassertheil-Smoller, J. Wactawski-Wende WHIMS Investigators Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2651 2662
67. S.R. Rapp, M.A. Espeland, S.A. Shumaker, V.W. Henderson, R.L. Brunner, J.E. Manson, M.L. Gass, M.L. Stefanick, D.S. Lane, J. Hays, K.C. Johnson, L.H. Coker, M. Dailey, D. Bowen, and WHIMS Investigators Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2663 2672
68. S.M. Resnick, M.A. Espeland, S.A. Jaramillo, C. Hirsch, M.L. Stefanick, A.M. Murray, J. Ockene, and C. Davatzikos Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study Neurology 72 2009 135 142
69. P.M. Maki, and E. Sundermann Hormone therapy and cognitive function Hum. Reprod. Update 15 2009 667 681